High throughput quantification of mutant huntingtin aggregates

Journal of Neuroscience Methods

Volumn 171, Issue 1, 2008, Pages 174-179

  Scotter, Emma L ^a   Narayan, Pritika ^a,b   Glass, Michelle ^a   Dragunow, Mike ^a,b  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Aggregate; Discovery 1; Huntington's

Indexed keywords

HUNTINGTIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOANALYSIS; CELL ASSAY; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; IMAGE ANALYSIS; IMAGE PROCESSING; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; RAT;

ANIMALS; CELL AGGREGATION; CELL SURVIVAL; DIAGNOSTIC IMAGING; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; HYDRAZINES; IMAGE PROCESSING, COMPUTER-ASSISTED; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PC12 CELLS; PROTEIN TRANSPORT; RATS; TIME FACTORS; TRANSFECTION; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 42749089622     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2008.02.007     Document Type: Article

References (18)

1. Aiken C.T., Tobin A.J., and Schweitzer E.S. A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 16 (2004) 546-555
2. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
3. Berthelier V., and Wetzel R. Screening for modulators of aggregation with a microplate elongation assay. Methods Enzymol 413 (2006) 313-325
4. Chen S., Berthelier V., Yang W., and Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 311 (2001) 173-182
5. Corcoran L.J., Mitchison T.J., and Liu Q. A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 14 (2004) 488-492
6. Hamuro L., Zhang G., Tucker T.J., Self C., Strittmatter W.J., and Burke J.R. Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay. Assay Drug Dev Technol 5 (2007) 629-636
7. Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S., et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci 99 (2002) 16400-16406
8. Kato M., Kinoshita H., Enokita M., Hori Y., Hashimoto T., Iwatsubo T., et al. Analytical method for B-amyloid fibrils using CE-laser induced fluorescence and its application to screening for inhibitors of B-amyloid protein aggregation. Anal Chem 79 (2007) 4887-4891
9. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., and Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci 96 (1999) 11404-11409
10. Kitamura A., Kubota H., Pack C.G., Matsumoto G., Hirayama S., Takahashi Y., et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 8 (2006) 1163-1170
11. Muchowski P.J., Schaffar G., Sittler A., Wanker E.E., Hayer-Hartl M.K., and Hartl F.U. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci 97 (2000) 7841-7846
12. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36 (2004) 585-595
13. Sanchez I., Mahlke C., and Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
14. Saudou F., Finkbeiner S., Devys D., and Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95 (1998) 55-66
15. Scherzinger E., Sittler A., Schweiger K., Heiser V., Lurz R., Hasenbank R., et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 96 (1999) 4604-4609
16. Skogen M., Roth J., Yerkes S., Parekh-Olmedo H., and Kmiec E. Short G-rich oligonucleotides as a potential therapeutic for Huntington's disease. BMC Neurosci 7 (2006) 65
17. Suhr S.T., Gil E.B., Senut M.C., and Gage F.H. High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc Natl Acad Sci 95 (1998) 7999-8004
18. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983